Latest Health News

Apiam Animal Health has entered a Process Deed granting Adamantem exclusivity to pursue a $0.88 per share acquisition proposal. The Independent Board Committee signals intent to recommend the deal, pending due diligence and shareholder approval.

Vitura Health reported a modest revenue increase to $124 million for FY2025, while net profit dipped 5.35% due to margin pressures and investment in new platforms. The company declared a fully franked dividend and highlighted growth in telehealth and medical services.

Praemium Limited reported robust FY25 results with revenue climbing 24.6% to $103 million and net profit after tax soaring 55% to $13.56 million, underpinned by strong growth in funds under administration and strategic product launches.

PeopleIN Limited posted a statutory net loss of $11.862 million for FY25, impacted by tough economic conditions and weather disruptions, while achieving significant cost savings and announcing a $6 million share buy-back.

Embark Early Education announces a fully franked interim dividend alongside robust first-half financial results, highlighting significant revenue and profit gains.

Elsight Limited has reported a remarkable 344% jump in first-half revenue to US$4.85 million, significantly narrowing its net loss and securing a substantial US$39 million capital raise to fuel growth.

nib Holdings reported a solid FY25 with underlying operating profit of $239.2 million and 3.2% policyholder growth, driven by digital innovation and operational efficiencies. The Group’s strategic focus on core health insurance and adjacent services sets the stage for continued momentum into FY26.

nib Group reported solid FY25 results with revenue growth to $3.6 billion and a 9.4% rise in net profit after tax, while maintaining its full-year dividend at 29 cents per share. The company’s Australian private health insurance business achieved record policyholder growth amid ongoing claims inflation and operational efficiencies.

nib holdings limited reported a 9.4% increase in net profit after tax to $198.6 million for FY25, alongside a 7.8% rise in group revenue to $3.6 billion. Despite a dip in underlying operating profit, the company declared a fully franked final dividend, maintaining its full-year payout at 29 cents per share.

Vita Life Sciences delivered a robust first half in 2025 with record revenue and profit growth, driven by strong performances in Australia and Southeast Asia. The company also raised its interim dividend and expanded marketing efforts.

Vita Life Sciences reported a robust half-year performance with revenue up 15.4% to A$45.5 million and a 12.2% rise in net profit, driven by strong growth in Australia and Southeast Asia. The company also increased its interim dividend to 4.5 cents per share, signaling confidence despite challenges in China.

IMDEX Limited reported resilient FY25 earnings highlighted by a record fourth quarter revenue and significant progress in its digital growth strategy, supported by strategic acquisitions and strong operational performance.